2024 ASCO Highlights Webinar
Webinar | English | 2024 | 60 Min
Image For Activity Cover
Credit Offered
1 ACCME Credit
1 Certificate of Attendance Credit

Join us for an exclusive webinar that delves into the most groundbreaking studies and updates presented at the 2024 American Society of Clinical Oncology (ASCO) meeting.This webinar will focus on pivotal advancements in the treatment and management of lung cancer, providing valuable insights for healthcare professionals involved in lung cancer care. Key topics include:

  • ADRIATIC Study: Discover the latest findings on durvalumab as a consolidation treatment for patients with limited-stage small-cell lung cancer (LS-SCLC).
  • Comparative Effectiveness of Early Palliative Care: Explore the comparative effectiveness trial that evaluates early palliative care delivered via telehealth versus in-person care among patients with advanced lung cancer.
  • LAURA Study: Gain insights into the primary results of the phase 3 LAURA study, which investigates the use of osimertinib (OSI) after definitive chemoradiotherapy (CRT) in patients with unresectable stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).
Live Activity Date: June 13, 2024
Enduring Activity Launch Date: June 26, 2024
Enduring Activity Expiration Date: June 24, 2025
This activity is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer including medical oncologists, thoracic surgeons, radiation oncologists, radiologists, pathologists, advanced practice nurses and physician assistants.
Upon completion of this educational activity, participants should be able to: 
  • Explain durvalumab's role in LS-SCLC treatment and evaluate its impact on patient outcomes based on the ADRIATIC study.
  • Analyze the benefits, challenges, and implications of integrating telehealth in palliative care.
  • Evaluate the impact of targeted therapy on disease progression and survival rates
  • Rebecca S. Heist, MD, Thoracic Oncologist, Associate Professor, Massachusetts Medical Cancer Center, Harvard Medical School, Boston, MA, USA
  • Alissa Cooper, MD, Thoracic Oncologist, Memorial Sloan Kettering Cancer Center, New York, NY, USA
  • Joseph A. Greer, PhD, Clinical Psychologist, Associate Professor, Massachusetts Medical Cancer Center, Harvard Medical School, Boston, MA, USA
  • Zofia Piotrowska, MD, MHS, Associate Professor of Medicine, Harvard Medical School, Boston, MA, USA
The following planners, speakers, reviewers, or staff have relevant financial relationships to disclose: 

Full Legal Name Commercial Interest Role Level of Participation in the Activity
Rebecca Heist Astra Zeneca Consultant Planner, Moderator
  Claim Therapeutics Consultant  
  Daichii Sankyo Consultant  
  Novartis Consultant  
  Regeneron Consultant  
  Sanofi Consultant  
  Lilly Consultant  
  EMD Serono Consultant  
  Biohaven Consultant  
  AbbVie Consultant  
Joseph Greer BeiGene Consultant Speaker
  Blue Note Therapeutics Research Funding  
  GlaxoSmithKline Speaker  
  Oxford University Press Royalties/Intellectual Property  
Alissa Cooper MJH Life Sciences Consultant Speaker
  Gilead Sciences Inc. Advisor  
Zofia Piotrowska Genentech/Roche Committee Speaker
  Eli Lilly Speaker Honorarium  
  Bayer Advisor  
  Janssen Advisor, Research Funding, Travel Support  
  Boehringer Ingelheim Advisor, Speaker Honorarium  
  Taiho Advisor  
  Astra Zeneca Advisor, Research Funding  
  Daiichi Sankyo Advisor, Research Funding  
  Merck Advisor  
  Sanofi Advisor  
  Takeda Advisor, Research Funding  
  Novartis Research Funding  
  Tesaro/GSK Research Funding  
  Cullinan Oncology Research Funding  
  AbbVie Research Funding  
Clarissa Baldotto Astra Zeneca Advisor/Speaker Planner
  Roche Advisor  
  Roche Brazil Speaker  
  Pfizer Advisor  
  Takeda Speaker  
  MSD Brazil Advisor/Speaker  
  Novartis Advisor  
  Janssen Advisor/Speaker  

"I have at present or have had within the last 24 months, a financial relationship with one or more ineligible companies."

These relationships with ineligible companies have been mitigated by the International Association for the Stufy of Lung Cancer (IASLC). 

All other presenters, planners, editors, or staff report no relationshops to disclose:

"I do not have at present nor have had within the last 24 months, any financial relationships with ineligible companies."

Accreditation Statement: 
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statements:

The International Association for the Study of Lung Cancer designates the live or enduring activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurse Practitioners and Registered Nurses
For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education).

Physician Assistants
The National Commission on Certification of Physician Assistants (NCCPA) states that the AMA PRA Category 1 Credits™ are acceptable for continuing medical education requirements for recertification.

International CPD Credit Reciprocity Agreements

The Royal College will recognize the number of participation hours as MOC Program Section 1 accredited group learning credits for group learning activities developed by Accreditation Council for Continuing Medical Education (ACCME)-accredited physician organizations (university, academy, specialty society, hospital department etc.) that are held within and outside of Canada. Agreement dates: November 1, 2019 to December 31, 2025.

European Union
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

The American Medical Association (AMA) and the Department of Healthcare Professions–Accreditation Section (DHP-AS), Ministry of Public Health–Qatar have renewed their CME agreement under which select activities approved for AMA PRA Category 1 Credit™ are eligible for conversion of the hours of participation to Department of Healthcare Professions Continuing Professional Development (DHP-CPD) credit. This agreement is in place through Dec. 31, 2026.
The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There are fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; participants should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:
  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out, if applicable.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test.
  4. Complete the activity evaluation to provide feedback for future programming and receive credit.
You may now view or print the certificate from your CME/CE Transcript. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Transcript and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Transcript.

*The credit that you receive is based on your membership profile.
If you need assistance with this activity, please email: education@iaslc.org.
Powered By